MedElevator
Войти в исследования Multicenter Retrospective Registry Study on BCG Use in Non-Muscle Invasive Bladder Cancer in Latin America: BLATAM (Bladder Cancer in Latin America) Group.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Villoldo Gustavo M, Gonzalez Matias Ignacio, Faune Alvaro Vidal, Molina Ricardo Castillejos, Montoya Fernando Meza, Salcedo José Gadu Campos, Vitagliano Gonzalo, Zampolli Hamilton, Lima Alcedir Raiser, Bengio Ruben, Camean Juan J, Alfieri Germán Ándres, Escalante Guido J P, Castro Ivan Edgar Bravo, Pita Hernando Rios, Escuder Juan, Covarrubias Francisco Rodriguez, Oliveira Maria Fernanda, Sanchez-Salas Rafael, Favre Gabriel Andrés, Guevara Eduardo, Videla Esteban Arismendi, Delgado Guillermo Martinez, Tobia Ignacio, Bachur Roberto F Villalba, Autran Ana Maria
Аннотация
MATERIALS AND METHODS: A multicenter retrospective study was carried out in collaboration with reference Urology Departments across Latin America. Data were collected using an electronic Case Report Form (CRF) from 2011 to 2021, capturing demographics, clinical presentation, treatment details, and follow-up of NMIBC patients treated with BCG. Statistical analyses included Kaplan-Meier survival analysis for relapse-free survival (RFS).
RESULTS: Data from 292 patients across five countries were analyzed, with a mean age of 70.3 years and a male prevalence of 74%. Smoking history was reported in 70.6% of patients. The mean time to the first BCG dose was 2.4 months post-TURBT, with 26.7% of patients exceeding the recommended 60-day window for induction initiation. While 84% of patients completed BCG induction, only 45.9% followed the recommended Lamm maintenance schedule. Delays in starting maintenance cycles were observed, with a median delay of over 36 days for the first cycle and 65 days for the second cycle. RFS at 1 year and 5 years for high-risk patients was 87.3% and 53.3%, respectively.
CONCLUSIONS: This study highlights critical deviations from recommended NMIBC management protocols in Latin America, including delayed BCG initiation and inconsistencies in maintenance therapy. These findings emphasize the need for standardized treatment protocols and improved adherence to international guidelines, which could enhance NMIBC patient outcomes in the region. Collaborative efforts are essential to develop region-specific strategies, improve data collection, and ultimately provide better care for bladder cancer patients in Latin America.